Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects

Centre Hospitalier Universitaire de Nīmes75 enrolled

Overview

The primary objective is to determine whether, during a rapid sequence intubation by etomidate, and succinylcholine Sellick maneuver, the administration of remifentanil at 2 different dosages (0.5 and 1.0 microgram per kg body weight), reduces potentially dangerous reactional tachycardia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Tachycardia

Interventions

0.5 µg/kg remifentanilDRUG

0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol

1.0 µg/kg remifentanilDRUG

1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol

NaClDRUG

an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol

Eligibility

Sex: ALLMin age: 65 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients requiring rapid sequence intubation for whatever reason. This includes the following: a full stomach, obesity, diabetic gastroparesis, gastroesophageal reflux * Patient able to give informed consent, and sign the consent. Exclusion Criteria: * Contraindication for the use of any drugs used (regardless of the patient group): a history of serious side effects, allergic reaction * Morbid obesity (Body Mass Index \> 40) * Emergency situation with unstable hemodynamics, and stabilization is impossible before induction * Inclusion in another research project within the past 3 months * The patient is not insured or beneficiary of a health insurance plan (for the French centers) * Patient under guardianship of any kind * Patient unable to give informed consent * Refusal to sign the consent form

Locations (2)

Centre Hospitalier Universitaire de Nîmes

Nîmes, Gard, France

Polyclinique Grand Sud

Nîmes, Gard, France

Outcomes

Primary Outcomes

Cardiac frequency (beats per minute)

Patient cardiac frequency (beats per minute) at the time of induction

Time frame: 15 minutes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.